CG
RXRX icon

Cutler Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Cutler Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$713 – 4233
2023
Q3 		$0 Sell
100
-200
-67% -$2K ﹤0.01% 4253
2023
Q2 		$2K Buy
+300
New +$2.1K ﹤0.01% 3099
2023
Q1 		– Sell
-900
Closed -$6K – 4576
2022
Q4 		$6K Sell
900
-100
-10% -$981 ﹤0.01% 3078
2022
Q3 		$10K Hold
1,000
– – ﹤0.01% 3148
2022
Q2 		$8K Sell
1,000
-140
-12% -$937 ﹤0.01% 3391
2022
Q1 		$8K Hold
1,140
– – ﹤0.01% 3802
2021
Q4 		$19K Sell
1,140
-460
-29% -$8.65K ﹤0.01% 3176
2021
Q3 		$36K Buy
+1,600
New +$45.3K ﹤0.01% 2808

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cutler Group's RXRX Position: Q4 2023 in Review

Cutler Group sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 100 shares — an estimated $713 sold.

Cutler Group first reported a position in RXRX in Q3 2021 and held it in 8 quarters. The position peaked at $36K in Q3 2021. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Cutler Group reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 100 Recursion Pharmaceuticals shares in Q4 2023, an estimated $713.
  • Cutler Group first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 8 quarters.
  • Cutler Group's Recursion Pharmaceuticals position peaked at $36K in Q3 2021.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.